Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Low dose finasteride causes only minor changes in PSA levels in men over 50 with BPH.

This study found that castration-resistant prostate cancers resistant to CYP17A1 inhibitors may still depend on steroids and could respond to therapies targeting de novo intratumoral steroid synthesis.

In this pilot study, Doxil at 60 mg/m² every 4 weeks showed activity against hormone-refractory prostate cancer but was limited by severe mucocutaneous toxicities.

This review discusses the adverse effects of 5α-reductase inhibitors, finasteride and dutasteride, on sexual, psychological, and vascular health, emphasizing the need for physicians to inform patients of these risks.

This discussion proposes a model to incorporate patients with hormone-resistant prostate cancer into the existing framework by redefining hormone resistance and exploring new therapeutic approaches.

This study suggests a possible link between late puberty onset and decreased prostate cancer risk, while over-the-counter ibuprofen use was associated with increased risk.

This review examines the pharmacological properties and potential clinical benefits of 5α‐reductase inhibition in prostate cancer but reports no new research findings.

This review addresses the effects of testosterone on brain development and examines both the established sex differences in brain functions and the debate surrounding structural dimorphism in neuropsychiatric conditions.

New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.

In this study conducted at Sir Ganga Ram Teaching Hospital in Pakistan, researchers found that preoperative use of finasteride significantly reduced intraoperative blood loss and shortened hospital stay for benign prostatic hyperplasia patients undergoing bipolar TURP, compared to those not receiving finasteride.

This thesis explores both environmental and genetic factors in prostate cancer, focusing on surrogate hormone markers, medical radiation, family history, and genetic polymorphisms related to DNA repair and hormone marker genes, but reports no new clinical findings.

This study systematically reviewed meta-analyses and Mendelian randomization studies to identify factors influencing prostate cancer risk, finding suggestive associations for physical activity, height, and smoking but no robust, convincing overlapping evidence across tested factors.

This article reviews the role and controversies of 5α-reductase inhibitors like finasteride and dutasteride in managing prostate cancer, without presenting new research results.

The authors concluded that preoperative treatment with finasteride for a month effectively reduced perioperative bleeding and shortened hospital stays in patients undergoing transurethral resection of the prostate.

This study found that testosterone replacement, with or without finasteride, did not lead to significant cognitive improvements over 36 months in healthy older men without prior cognitive impairment.

This study concluded that five-alpha-reductase inhibitors may reduce prostate cancer risk but could increase the risk of high-grade prostate cancer in men regularly screened for the disease.

This review summarizes how genetic studies using conditional β-catenin loss- and gain-of-function mice have advanced understanding of canonical Wnt signaling's role in embryonic development, adult stem cell maintenance, and cancer modeling.

This study found that flutamide-induced liver toxicity in prostate cancer patients was very rare, occurring in only 0.18% of cases with clinical manifestations, and symptoms resolved after discontinuing the drug.

In this large British study, prostate cancer risk was linked to ethnicity, family history, prostate enlargement, and PSA testing, while excess adiposity, smoking, diabetes, and certain lifestyle factors were associated with a reduced risk.

This study reported that adipose-derived stem cell-conditioned medium demonstrated anti-tumorigenic effects on B16 melanoma cells both in vitro and in vivo, indicating potential for future melanoma treatment.

This review discusses the management options for recurrent ischemic priapism, noting that ketoconazole, finasteride, and other hormonal therapies may be effective but can have significant side effects; it reports no new clinical findings.

This review highlights that several clinical and epidemiological studies link a diet high in terpenoid compounds with a decreased risk of prostate cancer, supporting the potential use of terpenoids as therapeutic ingredients in treating this disease.

Finasteride reduces the need for prostate surgery but may increase the risk of depression and persistent sexual side effects.

This meta-analysis reported that dietary intake of omega-3 or omega-6 fatty acids does not significantly impact prostate cancer risk.

This retrospective study observed no significant difference in the prevalence of incidental prostate cancer between suprapubic prostatectomy and transurethral prostate resection groups, with most tumors being well differentiated and early-stage.

This study found that the SRD5A2 A49T A variant is associated with an increased risk of prostate cancer, lower circulating 3α‐diolG levels, and a decreased risk of baldness.

This study found that African American men with prostate cancer have higher rates of somatic and germline androgen receptor mutations than Caucasian American men, which may contribute to ethnic differences in disease progression and outcomes.

The study created a test that found hormonal and toxic effects in plant and fungal extracts using prostate cancer cells.

This abstract discusses treatment options for benign prostatic hyperplasia and provides no new clinical results.

In this study, short-term finasteride treatment reduced apoptotic factors caspase-7 and IGFBP-3 in prostate cancer cells but did not significantly affect androgen receptor expression compared to placebo.